Cisplatin Nephrotoxicity: A Review

Thadhani, 1996, Acute renal failure, N Engl J Med, 334, 1448, 10.1056/NEJM199605303342207 Schrier, 2004, Acute renal failure: definitions, diagnosis, pathogenesis, and therapy, J Clin Invest, 114, 5, 10.1172/JCI200422353 Merouani, 1996, Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer, Kidney Int, 50, 1026, 10.1038/ki.1996.405 Kuhlmann, 1997, Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application, Nephrol Dial Transplant, 12, 2478, 10.1093/ndt/12.12.2478 Arany, 2003, Cisplatin nephrotoxicity, Semin Nephrol, 23, 460, 10.1016/S0270-9295(03)00089-5 Kroning, 2000, Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines, Cancer Chemother Pharmacol, 45, 43, 10.1007/PL00006741 Gately, 1993, Cellular accumulation of the anticancer agent cisplatin: a review, Br J Cancer, 67, 1171, 10.1038/bjc.1993.221 Ciarimboli, 2005, Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2, Am J Pathol, 167, 1477, 10.1016/S0002-9440(10)61234-5 Ludwig, 2004, Nephrotoxicity of platinum complexes is related to basolateral organic cation transport, Kidney Int, 66, 196, 10.1111/j.1523-1755.2004.00720.x Thomas, 2004, The role of advanced glycation in reduced organic cation transport associated with experimental diabetes, J Pharmacol Exp Ther, 311, 456, 10.1124/jpet.104.070672 Holzer, 2004, The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells, Mol Pharmacol, 66, 817, 10.1124/mol.104.001198 Townsend, 2003, Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells, J Am Soc Nephrol, 14, 1, 10.1097/01.ASN.0000042803.28024.92 Townsend, 2002, Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice, J Pharmacol Exp Ther, 300, 142, 10.1124/jpet.300.1.142 Nelson, 1995, Cysteine conjugate beta-lyase activity in human renal carcinomas, Cancer Biochem Biophys, 14, 257 Ekborn, 2003, Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig, Cancer Chemother Pharmacol, 51, 36, 10.1007/s00280-002-0540-5 Huang, 2001, Assessment of cisplatin-induced nephrotoxicity by microarray technology, Toxicol Sci, 63, 196, 10.1093/toxsci/63.2.196 Leussink, 2003, Renal epithelial gene expression profile and bismuth-induced resistance against cisplatin nephrotoxicity, Hum Exp Toxicol, 22, 535, 10.1191/0960327103ht393oa Thompson, 2004, Identification of platform-independent gene expression markers of cisplatin nephrotoxicity, Environ Health Perspect, 112, 488, 10.1289/ehp.6676 Arany, 2004, Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells, Am J Physiol Renal Physiol, 287, F543, 10.1152/ajprenal.00112.2004 Jo, 2005, MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis, Kidney Int, 67, 458, 10.1111/j.1523-1755.2005.67102.x Ramesh, 2005, p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice, Am J Physiol Renal Physiol, 289, F166, 10.1152/ajprenal.00401.2004 Lieberthal, 1996, Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis, Am J Physiol, 270, F700 Kawai, 2006, Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury, J Pharmacol Sci, 100, 65, 10.1254/jphs.FP0050661 Yilmaz, 2004, The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats, Pharmacol Res, 50, 287, 10.1016/j.phrs.2004.03.003 Davis, 2001, Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide, J Am Soc Nephrol, 12, 2683, 10.1681/ASN.V12122683 Kadikoylu, 2004, The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys, Hum Exp Toxicol, 23, 29, 10.1191/0960327104ht413oa Shino, 2003, Role of poly(ADP-ribose-)polymerase in cisplatin-induced injury in LLC-PK1 cells, Free Radic Biol Med, 35, 966, 10.1016/S0891-5849(03)00470-2 Badary, 2005, Naringenin attenuates cisplatin nephrotoxicity in rats, Life Sci, 76, 2125, 10.1016/j.lfs.2004.11.005 Durak, 2002, Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity, Drug Chem Toxicol, 25, 1, 10.1081/DCT-100108468 Sener, 2000, The protective effect of melatonin on cisplatin nephrotoxicity, Fundam Clin Pharmacol, 14, 553, 10.1111/j.1472-8206.2000.tb00440.x Weijl, 2004, Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study, Eur J Cancer, 40, 1713, 10.1016/j.ejca.2004.02.029 Chirino, 2004, Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats, BMC Pharmacol, 4, 20, 10.1186/1471-2210-4-20 Yildirim, 2003, Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats, Pharmacol Res, 47, 149, 10.1016/S1043-6618(02)00282-7 Winston, 1985, Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat, Am J Physiol, 249, F490 Tanaka, 2005, Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity, Am J Physiol Renal Physiol, 289, F1123, 10.1152/ajprenal.00081.2005 Kaushal, 2001, Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells, Kidney Int, 60, 1726, 10.1046/j.1523-1755.2001.00026.x Tsuruya, 2003, Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death, Kidney Int, 63, 72, 10.1046/j.1523-1755.2003.00709.x Dimanche-Boitrel, 2005, Role of early plasma membrane events in chemotherapy-induced cell death, Drug Resist Updat, 8, 5, 10.1016/j.drup.2005.02.003 Faubel, 2004, Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis, Kidney Int, 66, 2202, 10.1111/j.1523-1755.2004.66010.x Basnakian, 2005, Cisplatin nephrotoxicity is mediated by deoxyribonuclease I, J Am Soc Nephrol, 16, 697, 10.1681/ASN.2004060494 Ramesh, 2004, Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha, Kidney Int, 65, 490, 10.1111/j.1523-1755.2004.00413.x Ramesh, 2002, TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity, J Clin Invest, 110, 835, 10.1172/JCI200215606 Ramesh, 2003, TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure, Am J Physiol Renal Physiol, 285, F610, 10.1152/ajprenal.00101.2003 Yamate, 2002, Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats, Vet Pathol, 39, 322, 10.1354/vp.39-3-322 Guinee, 1993, Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy, Cancer, 71, 4050, 10.1002/1097-0142(19930615)71:12<4050::AID-CNCR2820711240>3.0.CO;2-7 Robbins, 1992, Long-term studies of cisplatin-induced reductions in porcine renal functional reserve, Cancer Chemother Pharmacol, 29, 309, 10.1007/BF00685950 Yamate, 2004, Effects of lipopolysac-charide on the appearance of macrophage populations and fibrogenesis in cisplatin-induced rat renal injury, Exp Toxicol Pathol, 56, 13, 10.1016/j.etp.2004.04.008 Hellwig-Burgel, 2005, Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions, J Interferon Cytokine Res, 25, 297, 10.1089/jir.2005.25.297 Cornelison, 1993, Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin, Gynecol Oncol, 50, 147, 10.1006/gyno.1993.1184 Isnard-Bagnis CDG, 2003, Anticancer drugs, 353 Daugaard, 1989, Cisplatin nephrotoxicity: a review, Cancer Chemother Pharmacol, 25, 1, 10.1007/BF00694330 Kollmannsberger, 1999, Late toxicity following curative treatment of testicular cancer, Semin Surg Oncol, 17, 275, 10.1002/(SICI)1098-2388(199912)17:4<275::AID-SSU9>3.0.CO;2-U Anand, 1993, Newer insights into cisplatin nephrotoxicity, Ann Pharmacother, 27, 1519, 10.1177/106002809302701219 Lajer, 2005, Magnesium depletion enhances cisplatin-induced nephrotoxicity, Cancer Chemother Pharmacol, 56, 535, 10.1007/s00280-005-1010-7 Kintzel, 2001, Anticancer drug-induced kidney disorders, Drug Saf, 24, 19, 10.2165/00002018-200124010-00003 Meyer, 1994, Cisplatin nephrotoxicity, Miner Electrolyte Metab, 20, 201 Goren, 2003, Cisplatin nephrotoxicity affects magnesium and calcium metabolism, Med Pediatr Oncol, 41, 186, 10.1002/mpo.10335 Lajer, 1999, Cisplatin and hypomagnesemia, Cancer Treat Rev, 25, 47, 10.1053/ctrv.1999.0097 Vickers, 2004, Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology, Toxicol Pathol, 32, 577, 10.1080/01926230490508821 Tanaka, 1986, Histopathological study of human cisplatin nephropathy, Toxicol Pathol, 14, 247, 10.1177/019262338601400215 Portilla, 2006, Metabolomic study of cisplatin-induced nephrotoxicity, Kidney Int, 69, 2194, 10.1038/sj.ki.5000433 Santoso, 2003, Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial, Cancer Chemother Pharmacol, 52, 13, 10.1007/s00280-003-0620-1 Dumas, 1990, Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II), Cancer Chemother Pharmacol, 26, 278, 10.1007/BF02897230 Daley-Yates, 1985, A study of the protective effect of chloride salts on cisplatin nephrotoxicity, Biochem Pharmacol, 34, 2363, 10.1016/0006-2952(85)90795-6 Hanigan, 2005, Stress response inhibits the nephrotoxicity of cisplatin, Am J Physiol Renal Physiol, 288, F125, 10.1152/ajprenal.00041.2003 Fu, 2006, Clinical application of oxaliplatin in epithelial ovarian cancer, Int J Gynecol Cancer, 16, 1717, 10.1111/j.1525-1438.2006.00654.x Piccart, 2001, Current and future potential roles of the platinum drugs in the treatment of ovarian cancer, Ann Oncol, 12, 1195, 10.1023/A:1012259625746 Grover, 2002, Functional impairment of renal organic cation transport in experimental diabetes, Pharmacol Toxicol, 90, 181, 10.1034/j.1600-0773.2002.900402.x Sarangarajan, 2004, Early onset of cisplatin-induced nephrotoxicity in streptozotocin-diabetic rats treated with insulin, Basic Clin Pharmacol Toxicol, 95, 66, 10.1111/j.1742-7843.2004.950204.x Esposito, 1996, Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II), Toxicol Appl Pharmacol, 140, 370, 10.1006/taap.1996.0233 Viale, 2000, Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?, J Pharmacol Exp Ther, 293, 829 Lynch, 2005, Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen, Hear Res, 201, 81, 10.1016/j.heares.2004.08.002 Nisar, 2002, N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity, Ren Fail, 24, 529, 10.1081/JDI-120006780 Karimi, 2005, Cisplatin nephrotoxicity and protection by milk thistle extract in rats, Evid Based Complement Alternat Med, 2, 383, 10.1093/ecam/neh103 Jones, 1992, Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds, Fundam Appl Toxicol, 18, 181, 10.1016/0272-0590(92)90044-I Capizzi, 1999, Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects, Semin Oncol, 26, 72 Myers, 1977, Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response, Science, 197, 165, 10.1126/science.877547 Treskes, 1993, WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach, Cancer Chemother Pharmacol, 33, 93, 10.1007/BF00685326 Kohda, 2005, Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation, Biochem Pharmacol, 70, 1408, 10.1016/j.bcp.2005.08.002 Schweyer, 2004, Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation, Br J Cancer, 91, 589, 10.1038/sj.bjc.6601919 Li, 2002, Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action, Lab Invest, 82, 585, 10.1038/labinvest.3780453 Deng, 2001, Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury, Kidney Int, 60, 2118, 10.1046/j.1523-1755.2001.00043.x Nagothu, 2005, Fibrate prevents cisplatin-induced proximal tubule cell death, Kidney Int, 68, 2680, 10.1111/j.1523-1755.2005.00739.x Willox, 1986, Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial, Br J Cancer, 54, 19, 10.1038/bjc.1986.147